FREMONT, Calif., April 18 /PRNewswire-FirstCall/ -- Abgenix, Inc.
(Nasdaq: ABGX) will hold a conference call on Tuesday, April 26, 2005 at
1:30 p.m. PT, 4:30 p.m. ET, to discuss first quarter financial results and to
provide an update on the company's antibody discovery, development, and
manufacturing activities. Bill Ringo, president and chief executive officer of
Abgenix, will host the call.
To participate in the teleconference, please dial 800-761-0748 fifteen
minutes before the conference begins. International callers should dial
617-614-2706. The pass code is 89600730. The call will also be webcast live at
http://www.abgenix.com. A replay of the call will be available until May 10, 2005 on
the company's website or by dialing 888-286-8010. International callers
should dial 617-801-6888. The replay participant code is 86920645.
About Abgenix
Abgenix is a biopharmaceutical company focused on the discovery,
development and manufacturing of human therapeutic antibodies. The company's
antibody development platform includes a leading technology and
state-of-the-art manufacturing capabilities that enable the rapid generation,
selection and production of high affinity, fully human antibody product
candidates to a variety of disease targets. Abgenix leverages its leadership
position in human antibody technology to build a diversified product portfolio
through its own development efforts and the establishment of collaborations
with multiple pharmaceutical and biotechnology companies. For more information
on Abgenix, visit the company's website at http://www.abgenix.com.
SOURCE Abgenix, Inc.
 back to top
Related links:
http://www.abgenix.com
CONTACT:
Ami Knoefler, Senior Director, Corporate
Communications and Investor Relations, of Abgenix, Inc.,
+1-510-284-6350, or +1-510-284-6605
|
